Linperlisib
As of the edition of 20 October 2026, Linperlisib is a small molecule: in active development; acts on PIK3CD.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 23, 1 stopped early
- Disease areas
- Blood and lymph; Immune system; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | O00329 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 3 | 1 | 0 | 1 |
| Phase 2 | 17 | 0 | 13 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| YingLi Pharmaceutical | Lead sponsor of trials | 2022 to now |
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2025 to now |